Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Glioblastoma 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Adenocarcinoma 1

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × ipatasertib × Clear all
NCT05498896 2026-05-08

BARBICAN

Queen Mary University of London

Phase 2 Active not recruiting
146 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

MedSIR

Phase 2 Completed
54 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03853707 2024-02-20

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

City of Hope Medical Center

Phase 1/2 Completed
28 enrolled 12 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡